NTLA - Intellia Therapeutics Inc (Healthcare: Biotechnology) Projected Earnings Date: 2024-11-06    (Delayed quote data   2025-01-03)
Last
 12.13		 Change
 ⇓ -0.09   (-0.74%)		 Volume
  2,820,291
Open
 12.22		 High
 12.53		 Low
 11.94
8EMA (Daily)
 12.09		 40EMA (Daily)
 13.97		 50EMA (Daily)
 14.55		 STO (Daily)
 17.077		 MACD Hist (Daily)
 0.120
8EMA (Weekly)
 13.604		 40EMA (Weekly)
 20.06		 50EMA (Weekly)
 21.68		 STO (Weekly)
 7.144		 MACD Hist (Weekly)
 -0.585
Company Profile
Intellia Therapeutics Inc is a genome editing company. It is focused on developing proprietary, potentially curative CRISPR/Cas9-based therapeutics. Its pipeline includes in vivo development programs targeting genetic diseases, including transthyretin amyloidosis and hereditary angioedema, and ex vivo programs which include Acute Myeloid Leukemia.
optionchance optionchance
⇒ Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com